FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely oncology, and can be used for treating cancer. That is ensured by administering a therapeutically effective amount of inositol tripyrophosphate (ITPP) and a therapeutically effective amount of a chemotherapeutic agent specified in a microtube-targeted agent (docetaxel, paclitaxel), a DNA-intercalating agent (cisplatin, doxorubicin) and a nucleoside metabolic inhibitor (gemcitabine, kalecitabine) into an individual in need thereof. The ITPP is administered before the chemotherapeutic agent has been administered.
EFFECT: invention enables reducing a dose of an anti-cancer chemotherapeutic agent when administering the ITPP and chemotherapeutic agents successively by the synergetic action of these drug preparations.
14 cl, 1 tbl, 13 dwg, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOUNDS AND COMPOSITIONS FOR STABILISATION OF HYPOXIA INDUCED FACTOR-2 ALPHA AS METHOD OF CANCER MEDICAL TREATMENT | 2012 |
|
RU2602498C2 |
| MONOCLONAL ANTIBODIES FOR TUMOUR TREATMENT | 2009 |
|
RU2531758C2 |
| PHARMACEUTICAL COMBINATION FOR CANCER TREATMENT | 2018 |
|
RU2801665C2 |
| COMBINATION THERAPY WITH AN ANTITUMOR ALKALOID | 2011 |
|
RU2605335C2 |
| COMBINED ANTICANCER THERAPY AND PHARMACEUTICAL COMPOSITIONS THEREFOR | 2005 |
|
RU2396960C2 |
| INHIBITION OR PREVENTION OF DISTURBED ANGIOGENIC REGULATION WITH USING RAPAMYCIN DERIVATIVES, AND PHARMACEUTICAL COMPOSITIONS CONTAINING RAPAMYCIN DERIVATIVE | 2006 |
|
RU2445093C2 |
| USE OF RAPAMYCIN DERIVATIVE | 2011 |
|
RU2483727C1 |
| COMBINATION THERAPY WITH ANTICANCER ALKALOID | 2018 |
|
RU2767664C2 |
| COMBINATION THERAPY WITH ANTITUMOR ALKALOID | 2011 |
|
RU2743643C2 |
| COMBINATION THERAPY WITH ANTITUMOR ALKALOID | 2018 |
|
RU2757373C2 |
